Eupraxia Pharmaceuticals Inc
🇨🇦XTSE.EPRXCanadaHealthcare
PriceCA$11.33-0.20 (-1.73%)
Latest anomalies
Very positive 8 detected in the last 120 days
- High: 1
- Medium: 6
- Low: 1
Daily return: an extreme move up, far outside its trailing 60-day range
Daily return: an extreme move up, far outside its trailing 60-day range
Overnight gap: a gap up from the prior close
Volume: a spike above the 20-day average
Overnight gap: a gap up from the prior close
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA29842P1053
- CUSIP
- 29842P105
Company
- Employees
- 33
- Headquarters
- Victoria, Canada
Market
- Shares outstanding
- 66.1M
- Market cap
- CA$573.25M
Highlights
- Market cap
- CA$573.25M
- EPS LTM
- -CA$0.44calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -25.85calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$0-100%down year on year
- Net income
- -CA$28.96M-8.13%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$30.9M-11.57%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Eupraxia Pharmaceuticals Inc is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker EPRX. Its market capitalisation is CA$573.25M, from 66.1M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$7.35 and CA$12.86, and the last close of CA$11.33 sits 72% of the way up that range. The company is headquartered in Victoria, Canada, and employs about 33 people.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.